Über die durch Sympathicomimetica ausgelöste, neurogene Vasodilatation

  • W. Osswald
  • J. Garrett


Neurogene Vasodilatation Sympathicomimetische Amine Ergotamin 


The hindlimb of the anesthetized dog was perfused at a constant flow rate. Intravenous administration of noradrenaline, adrenaline, dopamine, cobefrine, phenylephrine, norphenephrine, octopamine, heptaminol, tyramine, metaraminol, DMPP, m-bromophenyloxycholine and acetylcholine (after atropine) induced vasodilatation in the auto- or hetero-perfused limb. This effect was abolished by surgical interruption of the sympathetic innervation. Isoprenaline, N, N’-hexa-methylen-bis-noradrenaline, angiotensin, vasopressin, acetylcholine (without atropinization), 5-hydroxytryptamine and histamine did not cause neurogenic vasodilatation.

The magnitude of the vasodilatation (indicated by decreases in the perfusion pressure ranging from 10 to 120 mm Hg) depended both on the sensitivity of the experimental animal and on the dose of the drug; no correlation was found between the systemic pressor and the neurogenic vasodilator effects and even doses of adrenaline and dopamine which caused depressor effects produced vasodilatation, a response which was also observed after intraaortic administration of suitable drugs.

Ergotamine caused neurogenic vasodilatation but subsequently abolished it; for ergotamine different points of action could be shown (the perfused hindlimb, systemic circulation and central nervous system). Reserpine pretreatment, phentolamine, promethazine and pheniramine reduced or abolished the neurogenic vasodilatation, while propranolol, atropine and methsergide exerted no influence.

It is concluded that neurogenic vasodilatation cannot be accounted for solely by stimulation of baroreceptors and it is essentially abolished by surgical or pharmacological suppression of sympathetic function or impairment of the release and uptake mechanisms of nerve terminals; it appears to be initiated by stimulation of α-adrenergic receptors. The results obtained do not favour the participation of acetylcholine, histamine or 5-hydroxytryptamine as chemical mediators of neurogenic vasodilatation.


Neurogenic Vasodilatation Sympathomimetic Amines Ergotamine 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Beck, L.: Active reflex dilatation in the innervated perfused hind leg of the dog. Amer. J. Physiol. 201, 123–128 (1961).PubMedGoogle Scholar
  2. — Histamine as the potential mediator of active reflex dilatation. Fed. Proc. 24, 1298–1310(1965).PubMedGoogle Scholar
  3. Binet, L., et M. Burstein: Sur la vasodilatation péripherique d’origine adrénalinique. C.R. Soc. Biol. (Paris) 141, 630–638 (1947).Google Scholar
  4. Bogaert, M.G., and A.F. de Schaepdryver: Dopamine-induced neurogenic vasodilation in the hind leg of the dog. Arch. int. Pharmacodyn. 166, 203–207 (1967).Google Scholar
  5. Brody, M.J.: Neurohumoral mediation of active reflex vasodilatation. Fed. Proc. 25, 1538–1592 (1966).Google Scholar
  6. — Mechanisms of pharmacologic blockade of reflex vasodilatation. Fed. Proc. 27, 756 (1968).Google Scholar
  7. — D.W. du Charme, and L. Beck: Active reflex vasodilatation induced by veratrine and dopamine. J. Pharmacol. exp. Ther. 155, 84–90 (1967).PubMedGoogle Scholar
  8. Dörner, J.: Ist die auf nervalem Wege ausgelöste Gefäßdilatation nach intravenöser Injektion von Adrenalin und Arterenol die Folge einer Hemmung des Sympathicotonus? Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 221, 273–285 (1954).Google Scholar
  9. — W. Flacke u. C.R. Swaine: Zur Frage der Beteiligung atropinunempfindlicher Vasodilatatoren bei der neurogenen Gefäßdilatation nach Adrenalin und Noradrenalin. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 232, 306–308 (1957).CrossRefGoogle Scholar
  10. —, u. H.-J. Kuschke: Die Beeinflussung der neurogenen Adrenalin-und Arterenoldilatation der Skeletmuskelgefäße durch Novocain, Atropin und Physostigmin, zugleich ein Beitrag zur Frage der Existenz vasodilatatorischer Nerven. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 224, 368–377 (1955).CrossRefGoogle Scholar
  11. Folkow, B., and B. Uvnäs: Doadrenergic vasodilator nerves exist? Acta physiol. scand. 20, 329–337 (1950).PubMedCrossRefGoogle Scholar
  12. Frumin, M.J., S.H. Ngai, and S.C. Wang: Evaluation of vasodilator mechanisms in the canine hind leg; question of dorsal root participation. Amer. J. Physiol. 173, 428–463 (1953).PubMedGoogle Scholar
  13. Gayet, R., T. Gayet et M. Guillaumie: Actions vasomotrices de l’adrénaline sur les muscles. Processus péripherique vasoconstricteur et processus central vasodilatateur. C.R. Soc. Biol. (Paris) 97, 1145–1147 (1927).Google Scholar
  14. Glick, G., A.S. Wechsler, and S.E. Epstein: Mechanisms of reflex vasodilatation: assessment of the role of neural reuptake of norepinephrine and release of histamine. J. clin. Invest. 47, 511–520 (1968).PubMedCentralPubMedCrossRefGoogle Scholar
  15. Gruhzit, C. C, W.A. Freyburger, and G.K. Moe: The nature of the reflex vasodilatation induced by epinephrine. J.Pharmacol. exp. Ther. 112, 138–150 (1954).PubMedGoogle Scholar
  16. Jones, J.J.: Inhibition of the vasomotor system of the anesthetized dog by epinephrine and norepinephrine. Circulat. Res. 10, 156–159 (1962).PubMedCrossRefGoogle Scholar
  17. Levin, J.A., J.D. Bartlett, Jr., and L. Beck: Active reflex vasodilatation induced by intravenous epinephrine and norepinephrine in primates. J. Pharmacol. exp. Ther. 161, 262–270 (1968).PubMedGoogle Scholar
  18. McDonald, R.H., Jr., and L.I. Goldberg: Analysis of the cardiovascular effects of dopamine in the dog. J. Pharmacol. exp. Ther. 140, 60–66 (1963).Google Scholar
  19. Osswald, W.: Reversal of adrenergic vasodepression. Arch. int. Pharmacodyn. 126, 346–358 (1960).PubMedGoogle Scholar
  20. Rothlin, E.: The pharmacology of the natural and dihydrogenated alkaloids of ergot. Bull. Schweiz. Akad. med. Wiss. 2, 249–272 (1946/47).Google Scholar
  21. —, and R. Bircher: Allergy, the autonomic nervous system and ergot alkaloids. In: Progress in Allergy (Ed. P. Kallós), vol. 3, pp. 434–484. Basel: S. Karger 1952.Google Scholar
  22. Sakuma, A., and L. Beck: Pharmacological evidence for active reflex dilation. Amer. J. Physiol. 201, 129–133 (1961).PubMedGoogle Scholar
  23. Salzmann, R., W. Pacha, M. Taeschler, and H. Weidmann: The effect of ergotamine on humoral and neuronal actions in the nictitating membrane and the spleen of the cat. Naunyn-Schmiedebergs Arch. Pharmak. exp. Path. 261, 360–378 (1968).CrossRefGoogle Scholar
  24. Tuttle, R.S.: Histaminergic component in the baroreceptor reflex of the pyramidal cat. Fed. Proc. 25, 1593–1595 (1966).PubMedGoogle Scholar
  25. Uvnäs, B.: Cholinergic vasodilator nerves. Fed. Proc. 25, 1618–1622 (1966).PubMedGoogle Scholar
  26. Wellens, D.: Inhibition of norepinephrine induced reflex vasodilation in the dog hind limb. Arch. int. Pharmacodyn. 151, 281–285 (1964).PubMedGoogle Scholar
  27. — Peripheral inhibition of reflexogenic vasodilation induced by veratridine. Arch. int. Pharmacodyn. 172, 247–250 (1968).PubMedGoogle Scholar
  28. —, and E. Wauters: Norepinephrine-induced reflex vasodilation and adrenergic beta-receptors. Arch. int. Pharmacodyn. 159, 401–406 (1966).PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1969

Authors and Affiliations

  • W. Osswald
    • 1
  • J. Garrett
    • 1
  1. 1.Laboratório de FarmacologiaFaculdade de MedicinaPortoPortugal

Personalised recommendations